CoChat
Sign Up
Cited by 200Atrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsCardiac electrophysiology and arrhythmias

The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.

Superiority of ibutilide (a new class III agent) overdl-sotalol in converting atrial flutter and atrial fibrillation

Open access
Vos, M A, Golitsyn, S R, Stangl, K, Ruda, M Y, Van Wijk, L, Harry, J D, Perry, K T, Touboul, P, Steinbeck, G, Wellens, H J J·1998·Heart
DOI 10.1136/hrt.79.6.568PMC PMC1728725
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients. DESIGN: Double blind, randomised study. SETTING: 43 European hospitals. PATIENTS: 308 patients (mean age 60 years, 70% men, 48% with heart disease) with sustained atrial fibrillation (n = 251) or atrial flutter (n = 57) (duration three hours to 45 days) were randomised to three groups to receive a 10 minute infusion of 1 mg ibutilide (n = 99), 2 mg ibutilide (n = 106), or 1.5 mg/kg DL-sotalol (n = 103). Infusion was discontinued at termination of the arrhythmia. MAIN OUTCOME MEASURE: Successful conversion of atrial fibrillation or flutter, defined as termination of arrhythmia within one hour of treatment. RESULTS: Both drugs were more effective against atrial flutter than against atrial fibrillation. Ibutilide was superior to DL-sotalol for treating atrial flutter (70% and 56% v 19%), while the high dose of ibutilide was more effective for treating atrial fibrillation than DL-sotalol (44% v 11%) and the lower dose of ibutilide (44% v 20%, p < 0.01). The mean (SD) time to arrhythmia termination was 13 (7) minutes with 2 mg ibutilide, 19 (15) minutes with 1 mg ibutilide, and 25 (17) minutes with DL-sotalol. In all patients, the duration of arrhythmia before treatment was a predictor of arrhythmia termination, although this was less obvious in the group that received 2 mg ibutilide. This dose converted almost 48% of atrial fibrillation that was present for more than 30 days. Concomitant use of digitalis or nifedipine and prolongation of the QTc interval were not predictive of arrhythmia termination. Bradycardia (6.5%) and hypotension (3.7%) were more common side effects with DL-sotalol. Of 211 patients given ibutilide, two (0.9%) who received the higher dose developed polymorphic ventricular tachycardia, one of whom required direct current cardioversion. CONCLUSION: Ibutilide (given in 1 or 2 mg doses over 10 minutes) is highly effective for rapidly terminating persistent atrial fibrillation or atrial flutter. This new class III drug, under monitored conditions, is a potential alternative to currently available cardioversion options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/hrt.79.6.568

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 39 references

2 of the 39 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Volgman, 1996, Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter [abstract]., PACE, 19, 169
  2. Bianconi, 1995, Comparison of intravenously administered dofetilide versus amiodarone in the acute conversion of atrial fibrillation and flutter. A multicenter, randomized, double-blind, placebo controlled study [abstract]., Circulation, 92, 774
  3. 10.1161/01.CIR.92.7.1954 · DOI

Cited by

Sorted by citations

Items 101–199 of 199

Related

See all

Metadata

Authors
Vos, M. A., Golitsyn, S. R., Stangl, K., Ruda, M. Y., Van Wijk, L., Harry, J. D., Perry, K. T., Touboul, P., Steinbeck, G., & Wellens, H. J. J.
Affiliations
  • Refaja Ziekenhuis (NL)
  • aUniversity Hospital, Maastricht, Netherlands, bCardiology Research Centre, Moscow, Russia, cHumholdt University, Berlin, Germany, dSt Chr Ziekenhuis Refaja, Stadskanaal, Netherlands, ePharmacia & Upjohn, Crawley, West Sussex, UK, fPharmacia & Upjohn, Kalamazoo, Michigan, USA, gHospitaux de Lyon, Lyon, France, hKlinikum Grosehadern of the University of Munich, Germany
Corresponding author
Vos, M A
ORCID
Venue
Heart
Publisher
BMJ
Published
1998-06-01
Volume
79
Issue
6
Pages
568-575
ISSN
  • 1355-6037 (ISSN-L)
  • 1468-201X
DOI
10.1136/hrt.79.6.568
PMC
PMC1728725
OpenAlex
W2129291556
Cited by
200
References
39
Citations by year
2026: 1 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 5 · 2018: 2 · 2017: 9 · 2016: 8 · 2015: 6 · 2014: 5 · 2013: 4 · 2012: 4
FWCI
7.84
Type
journal article
Language
en
Open access
Locations
  • Heart (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
class III antiarrhythmic agents, atrial fibrillation, atrial flutter, drug safety, bradycardia, hypotension, QTc prolongation, digitalis, nifedipine
MeSH terms
Adult, Aged, Aged, 80 and over, Analysis of Variance, Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Double-Blind Method, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Prospective Studies, Sotalol, Sulfonamides, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review